Navigation Links
Cancer cell survival is not 'miR-ly' dependent on p53
Date:1/10/2011

Squamous cell carcinoma (SCC) is a common type of skin cancer. In this paper, Leif Ellisen and colleagues at Mass General Hospital investigated the p53-related proteins p63 and p73 in SCC cells, and discovered a feedback loop between p63, microRNAs (miRs), and p73. In a model of SCC, they found that inhibiting one of these miRs decreased tumor growth and made the cells more sensitive to chemotherapy, highlighting a new potential therapeutic target.

Squamous cell carcinoma (SCC) is a common type of skin cancer and remains one of the most resistant to available chemotherapies. Many cancer therapeutic strategies are directed at restoring the function of the tumor suppressor gene p53, because when active, cells are more sensitive to the DNA damage induced by chemotherapy. Other proteins related to p53, including p63 and p73, have also been implicated in cancer and cell sensitivity to chemotherapy. Both p63 and p73 are overexpressed in SCC, and are thought to play a role in chemoresistance. In new research, Leif Ellisen and colleagues at Mass General Hospital in Boston investigated the relationship between p63 and p73 in human and mouse SCC cells. They found that p63 negatively regulates the expression of a number of microRNAs (miRs), and that some of these miRs target p73 for inhibition. One of these, dubbed miR-193a, was also positively regulated by p73, suggesting a feedback loop that might promote chemoresistance in these cells. In a mouse model of SCC, the researchers found that inhibiting miR-193a decreased tumor growth and made the cells more sensitive to the chemotherapeutic agent cisplatin. The researchers believe that these findings identify a pro-survival mechanism in SCC, and may highlight new therapeutic targets in the fight against cancer.


'/>"/>

Contact: Karen Honey
press_releases@the-jci.org
Journal of Clinical Investigation
Source:Eurekalert

Page: 1

Related medicine news :

1. Geography May Influence Colon Cancer Screening Rates
2. For non-whites, geography plays key role in colon cancer screening
3. Race affects regional colorectal cancer screening disparities
4. Quality of life measures in breast cancer clinical trials
5. Quality of Life Key Measure in Breast Cancer Clinical Trials
6. Breast Cancer Outcome: Your Doctor Matters
7. VIB-K.U. Leuven scientists clear the way to alternative anti-angiogenic cancer therapy
8. TGen drug development teams with Oncoholdings to fight cancer
9. High dietary fat, cholesterol linked to increased risk of breast cancer
10. Cancer in a single catastrophe
11. Steering cancer inflammation to inhibit tumor growth and spread
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... DC (PRWEB) , ... March 30, 2017 , ... ... and organizations submitted a letter to President Trump expressing their support for an ... medical doctors, two Ph.D. scientists and one medical journalist, will hold a press ...
(Date:3/29/2017)... ... March 29, 2017 , ... In the United States alone, ... each year develop other types of metastatic brain tumors(3). Though most meningiomas are benign, ... efforts focus on finding more effective treatment options, the San Diego Gamma Knife ...
(Date:3/29/2017)... ... ... the main cause of hay fever in the United States, with an estimated 95 percent ... to July each year; with the worst time for sufferers being June and July. ... ) provide an effective defense against grass pollen; they are proven in independent studies to ...
(Date:3/29/2017)... ... March 30, 2017 , ... Sublime Naturals and its founder, Kathy Heshelow, are ... it has been used for thousands of years. , "The West has caught on, ... " Turmeric: How to Use it For Your Wellness. Overcome Inflammation, Enemy of the ...
(Date:3/29/2017)... (PRWEB) , ... March 29, 2017 , ... ... three Hours at a Walgreens store in Mississippi. AngioGenesis Labs, makers of HeartBoost, ... Stores in two southeastern states. Ingredients in HeartBoost, an over the counter heart ...
Breaking Medicine News(10 mins):
(Date:3/30/2017)... PHILADELPHIA , March 30, 2017  Lannett Company, ... the company voluntarily made a $25 million payment against ... $25 million payment, combined with the $75 million payment ... us approximately $5.5 million in annualized cash interest expense, ... executive officer of Lannett.  "Our business is solid and ...
(Date:3/30/2017)... Research and Markets has announced the ... & Forecast, By Type (Hemodialysis, Peritoneal Dialysis), By Product (Device, ... 2014 To 2025" report to their offering. ... The global ... 108.5 billion by 2025. Home-based dialysis ...
(Date:3/29/2017)... 29, 2017  Bodycad announced today that it ... 510(k) clearance for its Bodycad Unicompartmental Knee System, ... orthopaedic restoration. Bodycad is the first Canadian company ... implant system. Bodycad,s revolutionary Unicompartmental ... of the patient,s unique anatomical features and kinematics. ...
Breaking Medicine Technology: